We discovered three xenobiotics: CCX915, CCX140 (clinical trials- phase I and II), and TAK779 (preclinical) that have been used to target the extracellular region of CCR2. CCX915 is a highly selective inhibitor of the CCR2 chemokine receptor in multiple sclerosis and other autoimmune and inflammatory diseases. The gene discussed is CCR2; the disease is multiple sclerosis.